Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Fresenius Kabi Launches Posaconazole Injection for Fungal Infections | Contract Pharma

What are you searching for?

Sign in
Breaking News

Fresenius Kabi Launches Posaconazole Injection for Fungal Infections

Invests nearly $1 billion to double U.S. manufacturing capacity and enhance production and distribution network.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Fresenius Kabi introduced Posaconazole Injection, a generic substitute for Noxafil, for use in treating or preventing serious fungal infections in adults and children who have an increased chance of getting these infections due to a weakened immune system. 
 
Now available in the U.S. in a 300 mg per 16.7 mL vial, Posaconazole Injection is used to treat invasive aspergillosis, a serious fungal infection. It’s also used to prevent invasive aspergillus and candida infections in patients who are severely immunocompromised, including adults and pediatric patients age 2 or older. 
 
Posaconazole Injection is produced at the company’s pharmaceutical production site in Grand Island, NY. The company has invested nearly $1 billion to expand and update its U.S. pharmaceutical production and distribution network. More than 70 percent of the product units shipped in the U.S. by Fresenius Kabi are drugs listed on the FDA’s Essential Medicines List.
 
“We are doubling our U.S. manufacturing capacity to enhance the resilience of our supply chain, which helps assure fast, reliable service for our customers and the patients they serve,” said Lindsey Thomas, senior vice president of marketing of Fresenius Kabi USA. “Our investments will help patients gain access to the treatments they need – when and where they need them most.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics